New Friedreich Ataxia Study Findings Have Been Reported by Researchers at University of Bari 'Aldo Moro' (Microfluidic Formulation of Diazoxide-loaded Solid Lipid Nanoparticles As a Novel Approach for Friedreich's Ataxia Treatment).

Researchers at the University of Bari in Italy have reported new findings on the treatment of Friedreich's Ataxia (FRDA), a hereditary autosomal recessive disorder characterized by frataxin deficiency. The researchers developed solid lipid nanoparticles (SLNs) loaded with the drug diazoxide (DZX) using a microfluidic technique to improve its penetration of the blood-brain barrier (BBB) and reduce side effects. In vitro studies showed that SLN-DZX had enhanced permeability compared to plain DZX, and it also improved cell viability and reduced oxidative stress in FRDA fibroblast cells. The researchers concluded that SLN-DZX could be a potential therapeutic approach for FRDA with improved BBB penetration and reduced toxicity. [Extracted from the article]